Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study [0.03%]
增强肥胖经济模型：整合新型2型糖尿病进展及阻塞性睡眠呼吸暂停缓解——英国案例研究
Lieven Annemans,Erin Johansson,Erik Spaepen et al.
Lieven Annemans et al.
Purpose: This study presents an updated health economic model for evaluating the long-term cost-effectiveness of interventions in overweight and obesity, integrating new clinical evidence from the SURMOUNT clinical trial ...
Briana M Choi,Jeannie K Lee,Brian Erstad et al.
Briana M Choi et al.
Aims: This study aimed to review and compare existing value frameworks for digital health technologies (DHTs) and identify common domains to guide their evaluation. ...
Cost-effectiveness analysis of rapid antibiotic susceptibility testing as a point of care for patients with uncomplicated urinary tract infection in Japan [0.03%]
日本基层医疗中针对单纯性尿路感染患者的快速抗菌药物敏感性检测的成本效益分析
Hayato Niiro,Ayumu Yoshida,Fumiko Kino et al.
Hayato Niiro et al.
Background: Empirical antibiotic therapy for patients with urinary tract infections (UTIs) has contributed to the rise of overuse or use of inappropriate antibiotics, which is a significant public health concern. The intr...
Integrating single-inhaler triple therapy into global asthma management: clinical breakthroughs and economic realities [0.03%]
单吸入器三联疗法在哮喘治疗中的全球应用：临床突破与经济现实
Francesco Menzella
Francesco Menzella
Correction [0.03%]
改正通知书
Published Erratum
Journal of medical economics. 2026 Dec;29(1):1303. DOI:10.1080/13696998.2026.2663737 2026
A system dynamics modelling protocol to evaluate the impact of a health financing mechanism for breast cancer pharmacotherapies in Malaysia [0.03%]
乳腺癌药物治疗卫生融资机制的影响评估系统动力学建模协议——以马来西亚为例
Jing Sheng Lim,Weng Hong Fun,Kenneth Kwing Chin Lee et al.
Jing Sheng Lim et al.
Introduction: The rising cost of targeted breast cancer therapies challenges financial sustainability and equitable access in dual-tier health systems. In Malaysia, public cancer care is highly subsidized but budget const...
Cost-utility of implantable tibial neuromodulation (Revi) versus conservative therapy for urgency urinary incontinence in adults: a US payer perspective [0.03%]
从美国支付方角度出发分析植入式胫神经调制（ReVi）与成人尿急性尿失禁保守治疗的费用效果比
Cindy L Amundsen,Suzette E Sutherland,Sara M Lenherr et al.
Cindy L Amundsen et al.
Aims: Implantable tibial nerve neuromodulation (ITNM) represents a minimally invasive intervention for urgency urinary incontinence (UUI). This study evaluated the 3-year cost-utility of ITNM with an external wearable bat...
Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United States [0.03%]
与美国食品药品监督管理局批准的其他新型和仿制药相比，TAR-200治疗卡介苗无效、高危、非肌层浸润性膀胱癌原位癌患者的每响应者成本分析
Stephen Williams,Sang Cho,Laura Morrison et al.
Stephen Williams et al.
Aims: Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS) is aggressive and treatment options are suboptimal. TAR-200, a novel intravesical dru...
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial [0.03%]
司美格鲁肽与 tirzepatide 治疗肥胖或超重患者的美国成本效益分析：SURMOUNT-5 头对头 III 期临床试验结果
Erin Johansson,John P H Wilding,Navneet Upadhyay et al.
Erin Johansson et al.
Purpose: This study evaluated the cost-effectiveness (from the United States [US] societal perspective) of tirzepatide at its maximum-tolerated-dose (MTD) compared to semaglutide (MTD), both administered adjunct to a redu...
Cost-effectiveness analysis of capivasertib plus fulvestrant in the PIK3CA/AKT1/PTEN-altered subgroup with HR+/HER2- advanced breast cancer: a United States payer perspective [0.03%]
PIK3CA/AKT1/PTEN改变亚组激素受体阳性/her2阴性晚期乳腺癌中Capivasertib联合Fulvestrant治疗的 cost-effectiveness 分析：美国支付方视角
Xi Liang,Daniel C Malone,Chia Jie Tan
Xi Liang
Aims: Capivasertib plus fulvestrant has emerged as a promising targeted therapy for HR+/HER2- advanced breast cancer (ABC). This study evaluated the cost-effectiveness of capivasertib plus fulvestrant vs. fulvestrant mono...